SEARCH

SEARCH BY CITATION

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
HEP_24249_sm_suppinfofig1.tif148KSupporting Figure 1. Upregulation of CTLA-4 in responses to CMV and EBV in patients with CHB compared to healthy controls. Cumulative data of CTLA-4 expression in virus-specific CD8 T cells in CHB and healthy controls after 10 days culture and restimulation with HLA-A2 restricted immunodominant peptides derived from CMV or EBV, or OLP spanning the CMV pp65 protein.
HEP_24249_sm_suppinfofig2.tif133KSupporting Figure 2. CD4 T cells in CHB have an increased propensity to upregulate CTLA-4 compared to those from healthy controls. Cumulative data showing intracellular CTLA-4 after mitogenic stimulation in CD4 T cells from healthy controls and HBV infected individuals with low and high viral load (VL).
HEP_24249_sm_suppinfofig3.tif111KSupporting Figure 3. The propensity to upregulate CTLA-4 correlates with sAg levels in CHB patients. HBV multimer+ cells are stimulated with cognate peptide stained for intracellular CTLA-4.
HEP_24249_sm_suppinfofig4.tif293KSupporting Figure 4. No reduction of CTLA-4 and Bim in HBV-specific CD8 T cells upon viral load reduction with potent antivirals. Individual data for patients followed pre and 13-18 months after starting antivirals, showing no significant sustained changes in HBV-specific CD8 frequency or levels of Bim and CTLA-4 in these cells.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.